Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule
MADISON, Wis., March 22, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI) announced today that their two-year collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) to substantiate CDI's iCell® Cardiomyocytes as a predictive tool for assessing the potential cardiotoxic effects of developing drug candidates was completed early and is now transitioning into a standard supply agreement. Moving forward, iCell Cardiomyocytes, induced pluripotent stem cell (iPSC)-derived human heart cells, will be incorporated into Roche's drug development decision-making process.
CDI and Roche initiated their collaboration in March 2009 to interrogate CDI's iCell Cardiomyocytes against a well-categorized compound reference set intended to test the ability of the cardiomyocytes to predict drug-induced, potentially life-threatening, cardiac arrhythmias. These studies included longitudinal genetic and molecular characterizations of the cardiomyocytes and assessment of their performance across a variety of established and novel testing platforms designed to detect possible cardiotoxic effects of developing compounds early in their development cycle. Multiple publications based on this research are in preparation for submission to peer-reviewed journals.
"This transition to a standard supply agreement is an important milestone for CDI," said Chris Parker, Chief Commercial Officer of CDI. "CDI and Roche have developed and demonstrated, respectively, a more efficient tool to reveal potential cardiotoxicity in their drug development candidates. iCell Cardiomyocytes have proven to provide value to pharmaceutical drug discovery and development."
Robert Palay, CEO and Chairman of the Board of CDI, added, "We have developed iCell Cardiomyocytes as a cardiac cell model that truly reflects human biology. In addition, we have developed a manufacturing process that enables us to reliably deliver the cells in the quantity, quality and purity that our customers require to successfully accomplish their drug discovery and toxicity testing research. We look forward to continuing our relationship with Roche and enabling them to discover future drug candidates that could improve human health."
About Cellular Dynamics International, Inc.
Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPS cell technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.
SOURCE Cellular Dynamics International, Inc.
More by this Source
Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
Mar 21, 2013, 08:00 ET
Cellular Dynamics Announces the Production of Human iPSC Lines Under cGMP Conditions
Jan 17, 2013, 08:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.